Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 10/2001

01-08-2001 | Original Research Article

Postdischarge Adverse Drug Reactions in Primary Care Originating from Hospital Care in France

A Nationwide Prospective Study

Authors: Laurent Letrilliart, Thomas Hanslik, Michel Biour, Jean-Paul Fagot, Marguerite Guiguet, Dr Antoine Flahault

Published in: Drug Safety | Issue 10/2001

Login to get access

Abstract

Objective: To describe and estimate the incidence and preventability of postdischarge adverse drug reactions (ADRs) detected in primary care in France.
Design: Prospective study of patients referred to hospital by participating general practitioners (GPs). These GPs reported all cases of an adverse reaction to a drug instituted in hospital among patients who consulted them within 30 days of discharge.
Setting: 305 general practices from all French regions.
Patients: 7540 patients referred by GPs to private or public hospitals.
Main outcome measures: The incidence for postdischarge ADRs in primary care, and their preventability.
Results: 30 cases of postdischarge ADR were detected in 29 re-consulting patients, yielding a minimal incidence for France of 0.4 per 100 admissions (95% confidence interval 0.3 to 0.6). The ADRs were assessed as serious in 60% of cases. The main drug classes implicated were cardiovascular drugs (8 ADRs), oral anticoagulants (6), psychoactive drugs (4), antidiabetics (3), and opioid analgesics (3). Patients experiencing a postdischarge ADR were older than patients not experiencing one (median age: 77 vs 68 years; p = 0.004). Detected ADRs were considered preventable in 59% of cases.
Conclusions: Physicians and patients should be aware of the possible occurrence of postdischarge ADRs. Patient information in hospital, close postdischarge follow-up of patients at risk, and appropriate transmission of information between hospital physicians and GPs can help to prevent them.
Literature
1.
Larazou J, Pomeranz B, Corey P. Incidence of adverse drug reactions in hospitalized patients. JAMA 1998; 279: 1200–5CrossRef
2.
Imbs J, Pouyanne P, Haramburu F, et al. Iatrogenie médicamenteuse: estimation de sa prévalence dans les hôpitaux publics français. Thérapie 1999; 54: 21–7PubMed
3.
Ministère de l’Emploi et de la Solidarité. Annuaire des Statistiques Sanitaires et Sociales. 1998 ed. Paris: SESI, 1999
4.
Pokras R, Kozak L, McCarthy E, et al. Trends in Hospital Utilization, 1965-86. Am J Public Health 1990; 80: 488–90PubMedCrossRef
5.
Klein U, Klein M, Sturm H, et al. The frequency of adverse drug reactions as dependent upon age, sex, and duration of hospitalization. Int J Clin Pharmacol 1976; 13: 187–95
6.
Weigelt J, Dryer D, Haley R. The necessity and efficiency of wound surveillance after discharge. Arch Surg 1992; 127: 77–82PubMedCrossRef
7.
Iezzoni L, Mackiernan Y, Chalane M, et al. Screening inpatient quality using post-discharge events. Med Care 1999; 37: 384–98PubMedCrossRef
8.
Valleron A, Garnerin P. Computer networking as a tool for public health surveillance: the French experiment. MMWR Morb Mortal Wkly Rep 1992; 41: 101–10PubMed
9.
10.
11.
12.
Keissler D. Introducing MEDWatch: a new approach to reporting medication and device adverse effects and product problems. JAMA 1993; 269: 2765–8CrossRef
13.
Benichou C. Imputability of unexpected or toxic drug reactions. In: Benichou C, Bouche P, Caron J, et al., editors. Adverse drug reactions. A practical guide to diagnosis and management. New York (NY): J Wiley & Sons, 1994: 271–5
14.
Imbs JL, Pletan Y, Spriet A. Evaluation de la iatrogènese médicamenteuse évitable: méthodologie. Thérapie 1998; 53: 365–70PubMed
15.
16.
Vidal dictionary. 76th ed. Paris: Editions du Vidal, 2000
17.
Gardner M, Altman D. Statistics with confidence: confidence intervals and statistical guidelines. London: BMJ Books, 1989: 116–8
18.
Spino M, Sellers E, Kaplan H, et al. Adverse biochemical and clinical consequences of furosemide administration. Can Med Assoc J 1978; 118: 1513–8PubMed
19.
Pillans P, Coulter D, Black P. Angiooedema and urticaria with angiotensin converting inhibitors. Eur J Clin Pharmacol 1996; 51: 123–6PubMedCrossRef
20.
Skjelbred P. The effects of acetylsalicylic acid on swelling, pain and other events after surgery. Br J Clin Pharmacol 1984; 17: 379–84PubMedCrossRef
21.
van Kraaij DJ, Jansen R, Bouwels L, et al. Furosemide withdrawal in elderly heart failure patients with preserved left ventricular systolic function. Am J Cardiol 2000; 85: 1461–6PubMedCrossRef
22.
Dukes M. Meyler’s side effects of drugs. 13th ed. Amsterdam: Elsevier Science Publishers, 1996
23.
McAreavey D, Robertson J. Angiotensin converting enzyme inhibitors and moderate hypertension. Drugs 1990; 40: 326–45PubMedCrossRef
24.
The European atrial fibrillation trial study group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333: 5–10
25.
Fava M, Rosenbaum J, Hoog S, et al. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord 2000; 59: 119–26PubMedCrossRef
26.
Bocksberger J, Gex-Fabry M, Gauthey L, et al. Clomipramine therapy in the geriatric drug monitoring. Ther Drug Monit 1994; 16: 113–9PubMedCrossRef
27.
Egbert A, Parks L, Short L, et al. Randomized trial of postoperative patient-controlled analgesia vs intramuscular narcotics in frail elderly men. Arch Intern Med 1990; 150: 1897–903PubMedCrossRef
28.
United Kingdom Prospective Diabetes Study Group. United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310: 83–8
29.
Ytterberg S, Mahowald M, Woods S. Codeine and oxycodone use in patients with chronic rheumatic disease pain. Arthritis Rheum 1998; 41: 1603–2PubMedCrossRef
30.
Kjaersgaard-Andersen P, Nafei A, Skov O, et al. Codeine plus paracetamol versus paracetamol in longer-term treatment of chronic pain due to osteoarthritis of the hip: a randomised, double-blind, multi-centre study. Pain 1990; 43: 309–18PubMedCrossRef
31.
Wilton L, Pearce G, Mann R. A comparison of ciprofloxacin, norfloxacine, ofloxacine, azithromycin and cefixime examined by observational cohort studies. Br J Clin Pharmacol 1996; 41: 277–84PubMedCrossRef
32.
Royer R. Adverse drug reactions with fluoroquinolones. Therapie 1996; 51: 414–6PubMed
33.
Frykman E, Bystrom M, Jansson U, et al. Side effects of iron supplements in blood donors: Superior tolerance of heme iron. J Lab Clin Med 1994; 123: 561–4PubMed
34.
Perry M, Eaton W, Propert K, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987; 316: 912–8PubMedCrossRef
35.
Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164–70PubMedCrossRef
36.
Miremont G, Haramburu F, Begaud B, et al. Adverse drug reactions: physicians’ opinions versus a causality assessment method. Eur J Clin Pharmacol 1994; 46: 285–9PubMedCrossRef
37.
Kellaway GS. Intensive monitoring for adverse drug effects in patients discharged from acute medical wards. NZ Med J 1973; 78: 525–8
38.
Moride Y, Haramburu F, Requejo A, et al. Under-reporting of adverse drug reactions in general practice. Br J Clin Pharmacol 1997; 43: 177–81PubMedCrossRef
39.
Frankl S, Breeling J, Goldman L. Preventability of emergent hospital readmission. Am J Med 1991; 90: 667–74PubMed
40.
Hewitt J. Drug-related unplanned readmissions to hospital. Aust J Hosp Pharm 1995; 25: 400–3
41.
Mouquet M, Joubert M, Tudeau L. Les pathologies prises en charge à l’hôpital. Direction de la Recherche, des Etudes et de l’Evaluation et des Statistiques, Ministère de l’Emploi et de la Solidarité. Etudes et résultats 1999; 41: 1–8
42.
Moore N, Lecointre D, Noblet C, et al. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998; 45: 301–8PubMedCrossRef
43.
44.
Gurwitz J, Avorn J. The ambiguous relation between aging and adverse drug reactions. Ann Intern Med 1991; 114: 956–66PubMed
45.
Leape L, Brennan T, Laird N, et al. The nature of adverse events in hospitalized patients: results of the Harvard Medical Practice Study II. N Engl J Med 1991; 324: 377–84PubMedCrossRef
46.
Bates D, Miller E, Cullen D, et al. Patient risk factors for adverse drug events in hospitalized patients. Arch Intern Med 1999; 159: 2553–60PubMedCrossRef
47.
Beers M, Dang J, Hasegawa J, et al. Influence of hospitalization on drug therapy in the elderly. J Am Geriatr Soc 1989; 37: 679–83PubMed
48.
Omori D, Potyk R, Kroenke K. The adverse effects of hospitalization on drug regimens. Arch Intern Med 1991; 151: 1562–4PubMedCrossRef
49.
Seeger J, Kong S, Schumock G. Characteristics associated with ability to prevent adverse drug reactions in hospitalized patients. Pharmacotherapy 1998; 18: 1284–9PubMed
50.
Bates D, Leape L, Petrycki S. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med 1991; 8: 289–94CrossRef
51.
Bates D, Cullen D, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. JAMA 1995; 274: 29–34PubMedCrossRef
52.
Pearson T, Pittman D, Longley J, et al. Factors associated with preventable adverse drug reactions. Am J Hosp Pharm 1994; 51: 2268–72.PubMed
Metadata
Title
Postdischarge Adverse Drug Reactions in Primary Care Originating from Hospital Care in France
A Nationwide Prospective Study
Authors
Laurent Letrilliart
Thomas Hanslik
Michel Biour
Jean-Paul Fagot
Marguerite Guiguet
Dr Antoine Flahault
Publication date
01-08-2001
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 10/2001
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200124100-00006

Other articles of this Issue 10/2001

Drug Safety 10/2001 Go to the issue

Review Article

Antihypertensive Therapy and Cancer Risk

Practical Drug Safety

Prevention and Management of Antineoplastic-Induced Hypersensitivity Reactions

Leading Article

Clinical-Pharmacological Strategies to Assess Drug Interaction Potential During Drug Development

Review Article

Oral Contraceptives and Cancer

Review Article

Calcineurin Inhibitors and Post-Transplant Hyperlipidaemias